[Role of Ca-125 in the differential diagnosis of adnexal mass in breast cancer patients].
OBJECTIVE
Serum CA-125 is of value in differential diagnosis of benign and malignant adnexal masses, especially in postmenopausal women. In ovarian cancer preoperative CA-125 levels are related to tumor stage, histologic grade, but are not an independent prognostic factor.


METHODS
The aim of our study was to determine CA-125 serum level in women with ovarian tumor treated previously because of breast cancer.


METHODS
Due to our research, we examined 51 women operated on for adnexal masses in the Department of Oncological Gynaecology in Bydgoszcz, 1996 - 2002. All those patients were treated because of breast cancer previously.


RESULTS
In 19 women (37,3%) benign ovarian tumors were found, in 4 cases (7,8) - primary ovarian cancer whereas in 28 patients (54,9%) breast cancer metastases were detected. Based on CA-125 levels before surgery, correlation between CA-125 concentration and malignant histologic type was observed.


CONCLUSIONS
1. Higher CA-125 serum levels were found in a group of patients with metastatic adnexal masses compared to primary ovarian cancer. 2. In a group of women with breast cancer and ovarian tumor, metastatic adnexal masses were observed in more than 50% of cases.
Grabiec
Marek
M
Katedry i Kliniki Ginekologii Onkologicznej i Pielegniarstwa Ginekologicznego AM w Bydgoszczy. grabiecm@co.bydgoszcz.pl
Nowicki
Piotr
P
Walentowicz
Małgorzata
M
Greźlikowska
Urszula
U
Mierzwa
Tomasz
T
Chmielewska
Wiesława
W
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000276:immunology / Q000473:pathology*; D018394:CA-125 Antigen / Q000097:blood*; D003937:Diagnosis, Differential; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000276:immunology / Q000556:secondary* / Q000601:surgery; D011044:Poland; D011300:Preoperative Care / Q000379:methods; D012189:Retrospective Studies; D018570:Risk Assessment; D013997:Time Factors
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen